These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16059774)

  • 21. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE
    Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
    McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
    Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [ECTS--33rd European Symposium on Calcified Tissues].
    Praxis (Bern 1994); 2006 Jul; 95(27-28):1080. PubMed ID: 16888925
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of bone loss and gain in untreated and treated osteoporosis.
    Compston J
    Endocrine; 2002 Feb; 17(1):21-7. PubMed ID: 12014699
    [No Abstract]   [Full Text] [Related]  

  • 25. [Recombinant human parathyroid hormone--new perspectives for anabolic therapy of osteoporosis].
    Miazgowski T; Stefański A
    Pol Arch Med Wewn; 2004 Oct; 112(4):1249-54. PubMed ID: 15773439
    [No Abstract]   [Full Text] [Related]  

  • 26. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PTH injection for the treatment of osteoporosis].
    Sugimoto T
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():544-51. PubMed ID: 11979953
    [No Abstract]   [Full Text] [Related]  

  • 28. Ipriflavone: background.
    Gennari C
    Calcif Tissue Int; 1997; 61 Suppl 1():S3-4. PubMed ID: 9263607
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effects of estrogen on bone-turnover and its prevention and control of osteoporosis ].
    Lin SQ
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):728-9. PubMed ID: 15949374
    [No Abstract]   [Full Text] [Related]  

  • 30. [How to take charge of osteoporosis in women in 2005].
    Rev Infirm; 2005 Nov; (115):10-4. PubMed ID: 16375239
    [No Abstract]   [Full Text] [Related]  

  • 31. A rational approach to evidence gaps in the management of osteoporosis.
    Rosen CJ; Brown SA
    Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography.
    Fox J; Miller MA; Recker RR; Bare SP; Smith SY; Moreau I
    J Musculoskelet Neuronal Interact; 2005; 5(4):356-7. PubMed ID: 16340137
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of osteoporosis with parathyroid hormone].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anabolic activity of parathyroid hormone: a new therapeutic perspective in primary osteoporosis].
    Fiore CE; Tamburino G
    Ann Ital Med Int; 1987; 2(4):321-6. PubMed ID: 3079455
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys.
    Turner CH; Burr DB; Hock JM; Brommage R; Sato M
    Adv Exp Med Biol; 2001; 496():165-79. PubMed ID: 11783618
    [No Abstract]   [Full Text] [Related]  

  • 36. [Principles of differential pathogenesis-oriented therapy of various forms of osteopenia].
    Wessel G; Abendroth K
    Z Gesamte Inn Med; 1987 Oct; 42(19):533-6. PubMed ID: 3501206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoporosis: how should it be treated?
    Odvina CV
    J Investig Med; 2006 Apr; 54(3):114-22. PubMed ID: 16948394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of age on bone and renal responsiveness to parathyroid hormone infusion in man.
    Agnusdei D; Maioli E; Camporeale A; Zacchei F; Gerardi D; Gennari C
    J Endocrinol Invest; 1992; 15(9 Suppl 6):69-72. PubMed ID: 1300342
    [No Abstract]   [Full Text] [Related]  

  • 39. Priliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis.
    Reeve J; Tregear GW; Parsons JA
    Calcif Tissue Res; 1976 Aug; 21 Suppl():469-77. PubMed ID: 782668
    [No Abstract]   [Full Text] [Related]  

  • 40. Full length or fragments in hormone studies?
    Martin TJ
    J Bone Miner Res; 2006 May; 21(5):801; author reply 802. PubMed ID: 16734397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.